Mineralys Pays $200M for Full Lorundrostat IP Rights, Funds with $150M Stock Offering
Summary
Mineralys Therapeutics has paid $200 million to acquire full royalty-free intellectual property rights for its lead drug, lorundrostat, with potential additional commercial milestones up to $110 million. This news clarifies the financial terms of the IP acquisition, which was initially announced in an 8-K yesterday. The payment is being funded by a previously announced $150 million underwritten public offering of common stock, priced at $26.50 per share. This $200 million outlay is a significant investment, representing nearly 10% of the company's market cap, to gain full control over its key asset. While strategically positive for long-term control and profitability, the substantial cost and dilutive financing have already pressured the stock, which is now trading below the offering price. The FDA decision for lorundrostat, expected in Q4 2026, is the next major event.
At the time of this announcement, MLYS was trading at $24.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $12.59 to $47.65. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.